Avalo Therapeutics, Inc. - Common Stock AVTX 深 滬
等待開盤 09-04 09:30:00 美东时间
10.555
+1.535
+17.02%
華盛通- 最 高10.80
- 今 開8.94
- 成交量 60.85万股
- 最 低 8.73
- 昨 收 9.02
- 總市值 846.10万
- 52周最高 16.00
- 市盈率 靜 --
- 換手率 75.91%
- 52周最低 3.39
- 委 比 83.21%
- 總股本 80.16万
- 歷史最高 22032.00
- 量 比 4.35
- 振 幅 22.95%
- 歷史最低 3.39
- 每 手 1
- 風險率 5.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Initiates Coverage On Avalo Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Overweight rating.
08-15 20:55
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical invites shareholders and investors to an investor webinar on August 14, 2025, at 9 AM AEDT (August 13 at 4 PM PDT). The webinar will cover Q2 2025 financial and business results, with a Q&A session. Register at [link]. AVITA, a leader in acute wound care, highlights its FDA-approved RECELL System for burn and trauma wound treatment, along with other products like PermeaDerm and Cohealyx. A replay will be available post-event. For mo...
08-10 23:00
Avalo Therapeutics Q2 EPS $(1.92) Misses $(1.42) Estimate; Cash, Cash equivalents And Short-term Investments Were $113.3M As Of June 30
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of $(1.42) by 35.5 percent. This is a 86.35 percent increase over losses of $(14.07) per share
08-07 19:17
AVITA Medical to Announce Second Quarter 2025 Financial Results
AVITA Medical, Inc. announced it will report its Q2 2025 financial results after U.S. markets close on August 7, 2025. The company will host a conference call and webcast on August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time (1:30 p.m. Pacific Time) to discuss its financial results and recent business highlights. The live webcast and replay will be available on the company's Investor Relations website. AVITA Medical is a leading therap...
07-28 20:05
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics, a clinical-stage biotech company focused on treating immune dysregulation, announced that its management will participate in two investor conferences: the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, and the BTIG Virtual Biotechnology Conference 2025 on July 29-30, 2025. The company’s lead asset, AVTX-009, is a humanized monoclonal antibody targeting IL-1β for inflammatory diseases. Webcasts and re...
06-23 11:00
Avalo Therapeutics Highlights Potential of AVTX-009 in HS
The latest announcement is out from Avalo Therapeutics ( ($AVTX) ). On June 20,...
06-20 19:28
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Avalo Therapeutics has appointed Rita Jain, M.D., a leading rheumatologist with over two decades of experience in biopharma, to its Board of Directors. Jain's expertise in clinical development and regulatory affairs will support the advancement of AVTX-009, a Phase 2 anti-IL-1β monoclonal antibody targeting hidradenitis suppurativa (HS) and other inflammatory diseases. AVTX-009 inhibits IL-1β, a key driver of inflammation, with potential applicat...
06-18 11:00
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
AVITA Medical highlights data showing reduced hospital stay for burn patients treated with its RECELL technology, supported by a study analyzing over 6,300 patients. The spray-on skin cell therapy reduces hospital stays by 6.2 days (35.7%) and saves $300 million over five years compared to traditional grafting. The study underscores RECELL’s clinical and economic benefits, with the technology used in over 130 U.S. burn centers.
06-09 13:00
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™
AVITA Medical announced the first clinical publication on Cohealyx, a collagen-based dermal matrix, in the *Journal of Surgery*. The study, conducted at The Ohio State University Wexner Medical Center, showed that Cohealyx achieved autograft readiness in 5 to 10 days, significantly faster than the typical 2 to 4 weeks. Two patients with complex hand wounds saw excellent outcomes, with one ready for autografting by day 7 and the other by day 13. C...
06-05 20:04
HC Wainwright & Co. Assumes Avalo Therapeutics at Buy, Announces Price Target of $15
HC Wainwright & Co. analyst Mitchell Kapoor assumes Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $15.
06-02 18:43
